Abstract
Chromosome analysis is necessary for the risk classification of acute myeloid leukemia (AML). Marker chromosome (MC) is a fragmented chromosome whose origin cannot be identified from other chromosomes and originates from marked genomic instability. Although AML with MC (MC+) has a poor prognosis even after intensive chemotherapy, its influence on the outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. We retrospectively analyzed 162 AML patients after allo-HSCT. To evaluate the significance of MC, we compared it with other chromosomal abnormalities. Marker chromosome was detected in 14 (8.6%, MC+) patients (vs MC-, n=158). The 2-year overall survival (OS) in MC+ vs MC- was 26.8% vs 62.2% (P=.0098). The 2-year cumulative incidence of relapse (CIR) in MC+ vs MC- was 80.4% vs 35.5% (P=.0004). Among adverse-risk AML (AD-AML, n=36), AD-AML/MC+ (n=11) demonstrated a poorer 2-year OS (9.1%, vs AD-AML/MC- n=25, 58.3%, P=.0031) and higher 2-year CIR (89.6%, vs AD-AML/MC- 44.7%, P=.002). In multivariate analysis, MC (HR 3.08, 95% CI; 1.02-9.29, P=.046) and HCT-CI (HR 3.23, 95% CI; 1.00-10.4, P=.049) were independent risk factors for CIR among AD-AML. Our study suggests MC as a new independent factor for chromosome risk classification to further classify AD-AML.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
